China SFDA Official Expects H1N1 Vaccine Shots To Ready In July
This article was originally published in PharmAsia News
Executive Summary
Chinese authorities expect to have a vaccine against the A/H1N1 flu virus ready for inoculations by the end of July. They are counting on receipt of the strain in early June from the World Health Organization directly to drug makers, who are required to produce one following strict WHO protocols. The WHO had said slower-than-usual growth of the virus in laboratories meant the strain would not be available earlier than mid-July. The head of the State FDA's biology-production department said 11 drug companies are capable of producing seasonal flu vaccines, but only one can make the pandemic vaccine. (Click here for more
You may also be interested in...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.